ATXN7 anticorps (Middle Region)
Aperçu rapide pour ATXN7 anticorps (Middle Region) (ABIN927440)
Antigène
Voir toutes ATXN7 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- Middle Region
-
Réactivité croisée
- Rat (Rattus), Souris, Chien, Poulet
-
Purification
- Purified
-
Immunogène
- ATXN7 antibody was raised in rabbit using the middle region of ATXN7 as the immunogen
-
-
-
-
Indications d'application
-
WB: 0.2-1 µg/mL
Optimal conditions should be determined by the investigator. -
Commentaires
-
ATXN7 Blocking Peptide, (ABIN5612243), is also available for use as a blocking control in assays to test for specificity of this ATXN7 antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- Lot specific
-
Buffer
- Lyophilized powder. Add 50 µL of distilled water. Final antibody concentration is 1 mg/mL in PBS buffer.
-
Conseil sur la manipulation
- Avoid repeated freeze/thaw cycles.
-
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store at 4 °C, following reconstitution, aliquot and store at -20 °C.
-
-
- ATXN7 (Ataxin 7 (ATXN7))
-
Autre désignation
- ATXN7
-
Sujet
- ATXN7 is involved in neurodegeneration. ATXN7 acts as component of the STAGA transcription coactivator-HAT complex. ATXN7 mediates the interaction of STAGA complex with the CRX and is involved in CRX-dependent gene activation.The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Synonyms: Polyclonal ATXN7 antibody, Anti-ATXN7 antibody, ataxin 7 antibody, ADCAII antibody, OPCA3 antibody, SCA7 antibody.
Antigène
-